Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

Company Overview

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing medicines that target the chromatin regulatory system, which helps control how genes are expressed. The company’s research is aimed primarily at cancer and other diseases in which abnormalities in gene regulation contribute to disease progression.

Foghorn uses its proprietary Gene Traffic Control platform to study interactions among chromatin-regulating proteins and identify potential drug targets. Its product candidates have included therapies designed to inhibit or degrade components of the chromatin remodeling machinery, including programs directed at BRD9 and LSD1. These investigational medicines have been evaluated in clinical studies for selected cancers, although the company’s development priorities and pipeline may change as research progresses.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn was established by researchers including Cigall Kadoch and Gerald Crabtree, whose work helped advance understanding of chromatin biology. The company conducts biotechnology research and clinical development intended for use in global healthcare markets. Adrian Gottschalk has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $1.89 to $2.14
• 50-Day Range: $1.97 to $7.07
• 52-Week Range: $1.79 to $7.61
• Volume: 612,875 shs
• Average Volume: 336,366 shs
• Market Capitalization: $118.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.67
• Consensus Rating: Hold

Foghorn Therapeutics Stock Analysis - MarketRank™

Foghorn Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 547th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Foghorn Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on no strong buy ratings, 4 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Foghorn Therapeutics has a consensus price target of $6.67, representing about 238.4% upside from its current price of $1.97.

Amount of Analyst Coverage

Foghorn Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Foghorn Therapeutics are expected to decrease in the coming year, from ($0.86) to ($0.91) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Foghorn Therapeutics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Foghorn Therapeutics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.69% of the float of Foghorn Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Foghorn Therapeutics has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Foghorn Therapeutics has recently increased by 1.20%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Foghorn Therapeutics does not currently pay a dividend.

Dividend Growth

Foghorn Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: -0.19

News Sentiment

Foghorn Therapeutics has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for Foghorn Therapeutics this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for FHTX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.02% of the stock of Foghorn Therapeutics is held by insiders.

Percentage Held by Institutions

61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FHTX
• CIK: 1822462
• Web: foghorntx.com
• Phone: 617-586-3100
• Fax: N/A
• Employees: 106
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Foghorn Therapeutics: $6.67
• High Price Target: $12.00
• Low Price Target: $2.00
• Potential Upside/Downside: +234.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.30
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.28 million
• Net Margins: -175.78%
• Pretax Margin: -175.78%
• Return on Equity: N/A
• Return on Assets: -31.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.36
• Quick Ratio: 3.36

Sales & Book Value

• Annual Sales: $30.91 million
• Price / Sales: 3.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.92) per share
• Price / Book: -1.04

Miscellaneous

• Outstanding Shares: 59,380,000
• Free Float: 54,028,000
• Market Cap: $118.46 million
• Optionable: Optionable
• Beta: 3.01